Summaries of health policy coverage from major news organizations
Merck, U.K. Biotech Firm Reach Licensing Agreement for Research and Development of New HIV Treatments
Merck & Co. and the Cambridge Antibody Technology Group, a U.K. biotech firm, yesterday agreed to a five-year licensing agreement for the research and development of new HIV treatments, Reuters reports. Merck will provide its technology and knowledge of HIV biology in return for exclusive rights to any products developed through the collaboration. CAT will receive an "upfront" fee for access to its human phage antibody libraries, in addition to royalties from the sale of any products developed using its technology (Reuters, 10/10).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.